Conjugated therapeutics, including ADCs and AOCs, are reshaping the future of targeted therapies and creating new opportunities across oncology, immunotherapy, and precision medicine. As the field continues to evolve, next-generation development strategies are increasingly focused on enhancing efficacy, overcoming drug resistance, and achieving meaningful differentiation through discovery, screening, and pharmacological evaluation approaches.
This webinar will bring together perspectives spanning ADC discovery, preclinical pharmacology, clinical bioanalysis, and AOC DMPK strategy. Attendees will gain practical insights into ADC screening and pharmacology evaluation, key clinical bioanalytical considerations across PK, immunogenicity, and biomarker assessment, as well as integrated analytical strategies to support the development of complex conjugated modalities such as AOCs.
Key Learning Objectives:
- Understand emerging strategies for next-generation ADC development
- Learn advanced approaches for ADC screening and pharmacological evaluation
- Address key challenges and considerations in ADC clinical bioanalysis
- Explore integrated bioanalysis strategies for AOCs
Who Should Attend:
- DMPK scientists
- Bioanalytical scientists
- ADC/AOC researchers
- Oncology and targeted therapy researchers